Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

More people are getting cancer in their 20s, 30s, and 40s, and surviving, thanks to rapid advancement in care. Many will have ...

It comes as new analysis by Asthma and Lung UK found lung diseases were responsible for one in eight emergency hospital ...

Some of his patients are in their 20s and, increasingly, they are below age 50. The reasons for the increase in lung cancer ...

WHO says air pollution can trigger strokes, heart disease, lung cancer and other respiratory diseases. Some 900 people were ...

Years ago, McColgan said smoking was a way of life. He says it was advertised often on TV, considered a relaxer and even ...

"We can target very small lung nodules, some smaller than a centimeter, and biopsy them successfully," he said. "This technology makes a big difference for patients, allowing us to diagnose cancer ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...